<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201226049832N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-04-19</date_registration>
      <primary_sponsor>Shahroud University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of fentanyl with fentanyl and midazolam in pain control</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of fentanyl with fentanyl and midazolam in controlling pain in trauma patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-25</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>78</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53522</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Other, Randomization description: Patients will be randomly divided into 2 groups of 39 using Random allocation software.From the first eligible patient, the criteria for inclusion of treatment allocation based on randomization will beginInitially, the number 1 to 78 will be written on 78 envelopes, respectively.Then, inside each envelope, a sheet containing the code of the type of treatment of each patient will be specified based on the Random allocation software, which will determine the treatment of each patient.The written consent form of the study will be placed .After the arrival of each patient or identification in accordance with the criteria for entering an envelope in the order of the numbers that the type of treatment will be assigned in code, Blinding description: Participant: The use of placebo in addition to the current drug in one group of fentanyl and normal saline injections and in the second group of fentanyl and midazolam injections.
Outcome Evaluator: Measuring the patient's pain before and after the intervention by an emergency medicine resident who is unaware of how medications are administered to the patient.The data analyzer is not aware of how drugs are assigned to groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Trauma.</hc_freetext>
      <i_freetext>Intervention 1: Fentanyl injection based on weight levels (Weight 40 to 50 kg at 45 micrograms. Weight 50 to 60 kg at 55 micrograms. Weight 60 to 70 micrograms at 65 micrograms. Weight 70 to 80 kg at 75 micrograms. Weight 80 to 90 kg at 85 micrograms. Weight 90 to 100 kg and above 100 micrograms) and inject one milligram of normal saline. Intervention 2: Intervention group: Intravenous midazolam injection (1 mg under 50 kg. 2 mg 50 to 75 kg and 3 mg over 75 kg weight) and intravenous fentanyl injection based on weight levels (40 to 50 kg at 45 μg. 50 to 60 kg at 55 μg) Weight 60 to 70 micrograms at a rate of 65 micrograms. Weight 70 to 80 kg at a rate of 75 micrograms. Weight 80 to 90 kg at a rate of 85 micrograms. Weight 90 to 100 kg and above 100 micrograms).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All collected data will be shared after identifying individuals and analyzing them.

When:
The end of the year 1401

To whom:
For all researchers

Conditions:
For use in studies

Where to obtain:
Supervisor

How to obtain:
Justification for use via email correspondence

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>mozhgan sabzevari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahroud. 7th Tir Square. Shahroud University of Medical Sciences. School of Medicine. Third floor. Room 409</address>
        <city>shahrood</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3614773947</zip>
        <telephone>+98 23 3239 5009</telephone>
        <email>dr.sabzevari7@gmail.com</email>
        <affiliation>Shahroud University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mozhgan Sabzevari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahroud, Tehran St., 7th of Tir Square, Shahroud University of Medical Sciences, School of Medicine, Second Floor, Research Deputy</address>
        <city>Shahrood</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3614773947</zip>
        <telephone>+98 23 3239 5009</telephone>
        <email>dr.sabzevari7@gmail.com</email>
        <affiliation>Shahroud University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>People in the age group of 18 to 80 year
Mechanism of trauma multiple trauma and direct trauma
Obtaining informed consent
Stable hemodynamic status (including patients with systolic blood pressure above 90 mm Hg)
Patient consciousness is complete (GCS = 15)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy.Mentally retarded patients
Mentally retarded patients
Consumption of psychotropic drugs
Drug addicted patients</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G89.11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute pain due to trauma</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Fentanyl injection based on weight levels (Weight 40 to 50 kg at 45 micrograms. Weight 50 to 60 kg at 55 micrograms. Weight 60 to 70 micrograms at 65 micrograms. Weight 70 to 80 kg at 75 micrograms. Weight 80 to 90 kg at 85 micrograms. Weight 90 to 100 kg and above 100 micrograms) and inject one milligram of normal saline</i_keyword>
      <i_keyword>Intervention group: Intravenous midazolam injection (1 mg under 50 kg. 2 mg 50 to 75 kg and 3 mg over 75 kg weight) and intravenous fentanyl injection based on weight levels (40 to 50 kg at 45 μg. 50 to 60 kg at 55 μg) Weight 60 to 70 micrograms at a rate of 65 micrograms. Weight 70 to 80 kg at a rate of 75 micrograms. Weight 80 to 90 kg at a rate of 85 micrograms. Weight 90 to 100 kg and above 100 micrograms)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain control in patient trauma. Timepoint: at the time of referral , 30 and 60 minutes after the intervention. Method of measurement: using the Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Side effects of medications. Timepoint: 30 and 60 minutes after the intervention. Method of measurement: Examination by a specialist.</sec_outcome>
      <sec_outcome>Level of anxiety. Timepoint: At the time of referral, 60 minutes after referral. Method of measurement: Depression Anxiety Stress Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahroud University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-03-08</approval_date>
        <contact_name>research ethic committee   Shahroud university of medial science</contact_name>
        <contact_address>Shahroud University of Medical Sciences and Health Services, Hafte Tir Square Shahroud Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
